Fig. 1

Suppression of pkd2 mutants/morphants by TSA. (A and B) Treatment of 500 nM TSA from the shield stage leads to slight ventral curvature (B) on 2 dpf in wild-type embryos (wt) as compared to embryos treated with DMSO (A). (C–E) TSA can suppress the body curvature of pkd2/hi4166 mutant embryos. (C) shows mutant embryos treated with DMSO from 27 hpf on 2 dpf. Red lines depict the definition of curvature angle. (D) shows embryos treated with 500 nM TSA from 27 hpf on 2 dpf. With this treatment, mutant embryos are indistinguishable from wild-type siblings. (E) Average curvature angle in embryos treated with DMSO, 200 and 500 nM TSA. n = 5, *, P < 0.05, **, P < 0.0005. (F–H) Inhibition of kidney cyst formation in pkd2 morphants (pkd2mo) on 3 dpf by treatment of 100 nm TSA from the bud stage. (F) shows a pkd2 morphants treated with DMSO. The arrow points to the cyst. (F) shows a morphant treated with TSA. Insets show kidney cyst in F or the lack of cyst in G. (H) Average of percentage of embryos with kidney cysts from 3 independent experiments. Twenty-five to fifty embryos were examined in each experiment. ***, P < 0.005.